FDA delays action on closely watched Alzheimer’s drug
The Food and Drug Administration has decided to delay action on a closely watched Alzheimer's drug, donanemab, which was widely expected to approve this month. The FDA will instead require donanemab to be examined by a panel of independent…
Read More...
Read More...